A detailed history of Maplelane Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Maplelane Capital, LLC holds 160,000 shares of CRNX stock, worth $8.76 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
160,000
Previous 160,000 -0.0%
Holding current value
$8.76 Million
Previous $7.17 Million 14.04%
% of portfolio
0.5%
Previous 0.29%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$42.12 - $51.91 $6.74 Million - $8.31 Million
160,000 New
160,000 $7.17 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Maplelane Capital, LLC Portfolio

Follow Maplelane Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maplelane Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Maplelane Capital, LLC with notifications on news.